Keystone Joint Symposia—Advances in Neurodegenerative Disease Research and Therapy / New Frontiers in Neuroinflammation: What Happens When CNS and Periphery Meet?

Keystone, Colorado

More than 700 participants hailing from 35 countries gathered in Keystone, Colorado, June 17–21 for a joint Keystone symposium: Advances in Neurodegenerative Disease Research and Therapy; and New Frontiers in Neuroinflammation: What Happens When CNS and Periphery Meet? Researchers presented fresh findings on how microglial meddling steers neurodegeneration, on tau’s latest antics, on ApoE’s actions independent of Aβ, and how aging transmits from the blood into the brain. Participants jumped back and forth between the two side-by-side symposia, and packed poster sessions abuzz with intense discussions capped off each data-filled day. Check out Alzforum’s coverage for the highlights.

  1. Synaptic Tau Clangs the Dinner Bell for Hungry Microglia
  2. VCAM1: Gateway to the Aging Brain?
  3. ApoE Has Hand in Alzheimer’s Beyond Aβ, Beyond the Brain

American Academy of Neurology Annual Meeting 2018

Los Angeles, California

Will RNA molecules that bump up or tamp down gene expression live up to their potential? Results from RNA-targeting therapies presented at the 70th annual meeting of the American Academy of Neurology in Los Angeles suggest children with spinocerebellar ataxia continue to improve years after starting approved treatments. However, prices are high and so far, health gains are modest. Will similar approaches for Huntington’s disease, ALS, familial amyloid polyneuropathy, and tauopathies fare better?

View all 3 articles on this conference

AAT-AD/PD Focus Meeting 2018 - Advances in Alzheimer’s and Parkinson’s Therapies

Torino, Italy

Sorry for the acronym salad, folks, but it can’t be helped. The former International Geneva/Springfield Symposium on Advances in Alzheimer Therapy is merging with the International Conference on Alzheimer’s and Parkinson’s Diseases aka AD/PD to now be called Advances in Alzheimer’s and Parkinson’s Therapies Focus Meeting, aka AAT-AD/PD. That said, the two meetings will continue to alternate every March, except that AAT-AD/PD will cover the DLB/PD spectrum in addition to Springfield’s prior focus on AD. Your Alzforum reporters Madolyn Rogers and Gabrielle Strobel were chasing news at the inaugural AAT-AD/PD in Turin, Italy, and have culled the top stories for you.

View all 8 articles on this conference